This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
by Zacks Equity Research
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.
USNAPositive Net Change EDITNegative Net Change ALXOPositive Net Change
biotechnology biotechs earnings gene-editing medical pharmaceuticals
BMY Advances CELMoD Program With Positive Phase III Results
by Zacks Equity Research
BMY reports positive phase III SUCCESSOR-2 data as mezigdomide combo improves progression-free survival in relapsed multiple myeloma, boosting CELMoD program.
BMYPositive Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
by Zacks Equity Research
Incyte's Zynyz wins EU approval with chemotherapy for advanced anal cancer, marking the first systemic treatment for this indication.
NVSNegative Net Change INCYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis
by Zacks Equity Research
Bristol Myers wins FDA approval to expand Sotyktu for psoriatic arthritis after strong POETYK study data, adding a new indication for the TYK2 inhibitor.
BMYPositive Net Change AMGNPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
by Zacks Equity Research
RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.
RHHBYPositive Net Change USNAPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
by Zacks Equity Research
Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.
IDYANegative Net Change BDTXNegative Net Change
biotechs medical
NVO Stock Sheds Nearly $50B in Market Cap in a Month: Should You Sell?
by Ahan Chakraborty
Novo Nordisk erases most gains since Wegovy's 2021 launch as Lilly's drugs outperform its therapies in clinical studies and price cuts loom across its core GLP-1 franchise.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for March 9th
by Zacks Equity Research
ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.
HSYPositive Net Change ACMRNegative Net Change NESRNegative Net Change AMRXNegative Net Change ECGNegative Net Change
biotechs consumer-staples
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
by Zacks Equity Research
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
by Zacks Equity Research
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals